The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1677
May 29, 2023
View Complete Issue         Table of Contents 2019 
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
May 29, 2023 (Issue: 1677)
Eflapegrastim-xnst ((Rolvedon) [Spectrum]; previously called Rolontis), a granulocyte colony-stimulating factor (G-CSF) conjugated to an Fc fragment of human IgG4, has been approved by the FDA to decrease the incidence of infection, as manifested...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Eflapegrastim (Rolvedon) for Prevention of Chemotherapy-Induced Febrile Neutropenia
Article code: 1677b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.